Dyadic International (DYAI) Stock Price, News & Analysis

Company Overview

Dyadic International, Inc. is a biotechnology company that develops microbial-based technologies for producing proteins and other biological materials. Its platforms are designed to enable the cost-effective development and manufacture of vaccines, therapeutic proteins, enzymes, and other biologic products.

The company’s technology portfolio includes the C1 protein-production platform, which uses a proprietary fungal microorganism to produce recombinant proteins, and additional microbial expression systems intended to support applications in biopharmaceuticals, animal health, food and nutrition, and industrial biotechnology. Dyadic also develops its own product candidates and works with commercial, academic, and government partners to apply its platforms to vaccines, antibodies, enzymes, and other proteins.

Founded in 1979 and headquartered in Jupiter, Florida, Dyadic has pursued partnerships and technology applications serving markets in North America, Europe, and other international regions. The company is led by founder Mark Emalfarb, who has served as its chief executive officer and has been associated with the development and commercialization of Dyadic’s microbial protein-expression technologies.

Key Stats

• Today's Range: $0.44 to $0.50
• 50-Day Range: $0.40 to $1.21
• 52-Week Range: $0.34 to $1.60
• Volume: 85,910 shs
• Average Volume: 206,139 shs
• Market Capitalization: $17.81 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

Dyadic International Stock Analysis - MarketRank™

Dyadic International scored higher than 46% of companies evaluated by MarketBeat, and ranked 595th out of 891 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Dyadic International has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Dyadic International has a consensus price target of $3.00, representing about 574.8% upside from its current price of $0.44.

Amount of Analyst Coverage

Dyadic International has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Dyadic International are expected to grow in the coming year, from ($0.15) to ($0.08) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Dyadic International is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dyadic International is -1.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Dyadic International has a P/B Ratio of 14.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.72% of the float of Dyadic International has been sold short.

Short Interest Ratio / Days to Cover

Dyadic International has a short interest ratio ("days to cover") of 1.01, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Dyadic International has recently increased by 30.02%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Dyadic International does not currently pay a dividend.

Dividend Growth

Dyadic International does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.61

News Sentiment

Dyadic International has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Dyadic International this week, compared to 3 articles on an average week.

Company Ownership

• Score: 1.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Dyadic International insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,165.00 in company stock.

Percentage Held by Insiders

20.90% of the stock of Dyadic International is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

27.95% of the stock of Dyadic International is held by institutions.

Company Calendar

• Last Earnings: 8/12/2026
• Today: 9/30/2026
• Next Earnings (Estimated): 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:DYAI
• CIK: 1213809
• Web: www.dyadic.com
• Phone: (561) 743-8333
• Fax: 561-743-8343
• Employees: 5
• Year Founded: 1979

Price Target and Rating

• Average Price Target for Dyadic International: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: +574.8%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$7.36 million
• Net Margins: -201.43%
• Pretax Margin: -201.43%
• Return on Equity: -2,920.31%
• Return on Assets: -84.77%

Debt

• Debt-to-Equity Ratio: 4.08
• Current Ratio: 1.65
• Quick Ratio: 1.65

Sales & Book Value

• Annual Sales: $3.09 million
• Price / Sales: 5.76
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.03 per share
• Price / Book: 14.82

Miscellaneous

• Outstanding Shares: 40,060,000
• Free Float: 31,691,000
• Market Cap: $17.81 million
• Optionable: Optionable
• Beta: 0.96